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Although many patients with Hodgkin lymphoma (HL) achieve
sustained remission following ﬁrst-line chemotherapy with or
without consolidation radiotherapy, there remain 5–10% who are
refractory to ﬁrst-line therapy and up to 30% of patients relapse.1,2
Second-line treatment with multi-agent salvage chemotherapy
followed by high-dose chemotherapy and autologous stem cell
transplantation (ASCT) provides durable clinical beneﬁt in around
50% of patients or more.2,3
Currently, treatment options for patients with recurrence of HL
post ASCT include: further salvage chemotherapy, reduced
intensity conditioning allogeneic stem cell transplant (alloSCT) in
younger patients, palliative chemotherapy (often gemcitabine
based) and/or radiotherapy, trials of new agents and occasionally
a second ASCT.2,4 However, there is little information about the
use and effectiveness of these strategies and no guidelines or
standard of care recommended in the United Kingdom. We
undertook a multicentre retrospective observational study to
better understand UK treatment pathways and resource use in
order to inform future clinical decisions and further research
required. Treatment patterns, National Health Service (NHS)
resource use and treatment-associated outcomes were observed.
Five UK NHS hospitals with specialist services providing stem cell
transplantation for HL participated in our study. These centres were
selected to provide a geographical distribution across the United
Kingdom and represent ~ 20% of all NHS centres with specialist
stem cell transplantation services. We identiﬁed eligible patients via
the hospital transplant database or equivalent, which was reviewed
by clinical staff with routine access to the database for clinical care.
The study eligibility period was the 5 years to 2009, which allowed
treatment of subsequent recurrence of HL to be studied in a recent
time frame, but with a sufﬁcient follow-up period available to
describe the whole management pathway and outcomes. This
period was expected to provide a total of ~ 60 eligible patients.
There was no sampling of patients due to the rarity of the disease
and small numbers who have recurrence of post ASCT HL; the
whole cohort was included to ensure all treatment pathways were
described. All data were obtained by review of medical records by
NHS clinical staff and clinicians then provided anonymised, coded
study data to external researchers for analysis.
All data were collected retrospectively to the patient’s death or up
to the most recent relapse or treatment received. Summary data on
patient characteristics and treatment pathways were collected from
the time of diagnosis to the time of ASCT. More detailed data on the
treatment regimens, number of cycles, courses of radiotherapy,
hospital resources and patient outcomes were collected for the post
ASCT period. Data were pooled from all the centres for analysis and
stratiﬁed by centre to check for large differences in treatment patterns
between them. However, due to the small size of the available cohort
at each centre, no results are presented from these comparisons.
Costs were calculated by multiplying the number of units per
resource item by the cost of each item for every patient.
Treatment costs were calculated using the resource usage
variables described above, drug costs were obtained from the
British National Formulary5 and other resource values from the
Department of Health.6 There was no cost listed for alemtuzumab;
therefore a representative cost was used. Mean costs were
estimated by treatment group: second ASCT, allo, chemotherapy
alone and best supportive care (BSC) were considered appropriate
as they include differences in observation periods and patient
proﬁles for the different treatment options.
All 40 patients who met the eligibility criteria were included in
our study (range 5–13 per centre). Baseline characteristics were
evenly balanced and our cohort at diagnosis included 10 (25.0%)
patients who were Ann Arbor stage I/IIA (early stage), 29 (72.5%)
who were Ann Arbor stage IIB/III/IV (advanced stage) and 1 (2.5%)
for whom the stage was not recorded. Of the 10 early stage
patients, 8 (80.0%) received ABVD (doxorubicin, bleomycin,
vinblastine, dacarbazine) as their ﬁrst regimen pre-ASCT, one
received radiotherapy only and one received OEPP/COPP (vincris-
tine, epirubicin, procarbazine and prednisone/cyclophosphamide,
vincristine, procarbazine and prednisone; two cycles of each). Six
(60.0%) of these patients achieved complete remission or
‘complete remission uncertain’. Of the 29 advanced stage patients,
23 (79.3%) received ABVD as their ﬁrst regimen pre-ASCT with four
achieving ‘complete remission uncertain’. Overall, seven (24.1%)
advanced stage patients achieved complete remission or
‘complete remission uncertain’ in response to ﬁrst-line therapy.
Allogeneic transplantation was emerging as the standard goal
for consolidation of patients following failure of ASCT during this
period. All involved centres considered patients with responsive
disease and appropriate organ function to be potential candidates
for such consolidation. Lack of an appropriate donor was an
uncommon reason for not proceeding, as was patient preference.
Recognising some limitations with respect to retrospective studies
and ascribing treatment intent in all cases, our study demon-
strated that treatment of HL post ASCT was highly variable
in terms of intensity, outcome and resource use. In relation
to recurrence and treatment pathways, the median time to
recurrence of HL post ASCT was 6 months (range 0.23–65 months).
Following recurrence post ASCT, 19 (47.5%) patients received
palliative chemotherapy only, 15 (37.5%) received chemotherapy
followed by alloSCT or a second ASCT and 6 (15.0%) received BSC.
The most commonly received ﬁrst- and second-line chemotherapy
regimen following recurrence post ASCT was platinum-based. Of
the 34 (85.0%) patients who received chemotherapy (including
alloSCT and second ASCT), 12 (35.3%) received a second regimen,
6 (17.6%) a third regimen and 2 (5.9%) a fourth regimen.
In relation to 3-year survival we found that it was highest
among patients who received alloSCT. Following relapse post
ASCT the proportions of patients surviving to 3 years were 71.5%
in the alloSCT group, 5.9% in the palliative chemotherapy group
and 0% in the BSC group. Furthermore, a separate analysis of time
from relapse to death or last follow-up also indicated a substantial
advantage of alloSCT over other treatment pathways.
Overall resource use and mean total costs per patient post ASCT
recurrence is summarised in Table 1. AlloSCT and palliative
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chemotherapy were associated with the highest number of
outpatient visits during the follow-up period (30.0 and 27.9 visits
per patient, respectively), longest durations of hospitalisation and
number of scans (8.9 and 7.7, respectively). However, fewer day
case visits overall were recorded among patients receiving
alloSCT compared with those receiving palliative chemotherapy
or chemotherapy followed by second ASCT. Finally, BSC and
chemotherapy followed by second ASCT were associated with the
lowest resource use overall.
AlloSCT was the most costly intervention overall (mean £110
374/patient), followed by palliative chemotherapy. A large
proportion of the costs associated with alloSCT were due to the
procedure itself: ranging between £34 783–£44 059 depending on
the exact protocol (accounting for 31.5–39.9% of the total cost).6
However, the period over which the costs were accrued differed
for each treatment (Figure 1). The mean length of follow-up was
substantially greater in the alloSCT group (1253 days) compared
with the other treatment groups (palliative chemotherapy:
627 days; BSC: 458 days; second ASCT: 274 days).
Recent studies found the median overall survival following relapse
post ASCT to be only 25–32 months,7,8 and a study of patients with
relapsed HL demonstrated 5-year overall survival rates of 42% in 24
patients post ASCT and 1-year overall survival rates of 80% in ﬁve
patients following allo.9 Our results compare favourably with these
data and the appropriate selection of patients most likely to beneﬁt
from alloSCT is likely to have contributed to the high survival rate.
Crucially, the demographic data indicate that these patients were
younger and had relapsed later than those treated with palliative
treatment or BSC; this is important as outcomes are generally
considered poor for patients with early relapse (within 6–12 months
of ASCT).4 Although viable alternatives to transplant for recurrent HL
are lacking, novel biological and targeted therapies, and immune
checkpoint inhibitors, have shown promising results10 and are
welcome additions to the growing number of treatment strate-
gies.11 However, their place in therapy is still being established.11
To our knowledge this is the ﬁrst report of health-care resource
use for patients who relapse post ASCT. In general, palliative
chemotherapy and alloSCT were associated with the greatest level
of health-care resource use compared with BSC and chemother-
apy followed by second ASCT (Table 1). In particular, patients
receiving alloSCT tended to have the longest overall duration of
hospital stay, around 70% longer than patients receiving palliative
chemotherapy. It is not surprising, therefore, that the overall
treatment costs were greatest for alloSCT with more than 30% of
total costs due to the alloSCT itself. However, patients receiving
alloSCT had much greater survival or longer follow-up compared
with those receiving other treatments. The high treatment cost of
alloSCT must, therefore, be considered in the context of
substantially improved survival and a comparatively limited
increase in health-care resource use overall.T
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Figure 1. Patient follow-up in days.
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Limitations of this study were typical of any study reliant on
retrospective data, including the availability and completeness of
health records, which subsequently limited the completeness of
treatment details reported in our results. Our study suggests that
optimal disease management requires a choice of appropriate
treatment aimed at achieving a balance between efﬁcacy and
toxicity in circumstances where what may be suitable for one
patient may not be appropriate for another. We found that
treatment approaches, survival and resource use in patients with
recurrent HL post ASCT is diverse. Management of such patients
requires further evaluation, including greater understanding of
treatment planning and decision-making at post ASCT relapse,
particularly given the emergence of newer therapeutic agents with
activity in such patients. Larger patient numbers treated according
to evolving standards of care and with longer follow-up are
necessary to improve the current understanding of the implications
of HL management on health-care budgets and patient outcomes.12
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